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Aim: Evaluation of the antitumor activity of the new drug Dekoglitz in 
animals with tumor strains of Sarcoma 45 in comparison with the drug 
dekocin, from which it was obtained, as well as with 5-fluorouracil and 
etoposide, and on ovarian tumors (OT) in comparison with the drug de-
kocin and identification of the effect of Dekoglitz on NA synthesis and 
internucleosomal DNA degradation. Methods: The study of preparations 
was carried out on 68 outbred rats with transplanted C-45 and OT tumors. 
The alkylating effect of the drugs was studied on cells tumor of Sarcoma 
180. Results: The antitumor activity of dekoglitz on Sarcoma 45 was 
high, about 98/96%, with a remission rate of 80%. Its effect was 28-24% 
higher than that of dekocin. On OT, the effect of decoglitz with intraperi-
toneal administration reached 89/76% with a remission rate of 40%, with 
oral administration 96/86% with a remission rate of 60%. Conclusion: 
The study of the new drug Dekoglitz on animals with a tumor of Sarcoma 
45 revealed its higher activity (by 20-27%) in comparison with the orig-
inal Dekocin, 5-fluorouracil and etoposide with a lower level of side ef-
fects. On OT, the effect of Dekoglitz was 35-40% higher, especially after 
oral administration. Apparently, the great ability to suppress the synthesis 
of NA and carry out internucleosomal degradation and fragmentation of 
tumor DNA by the new drugs dekoglitz explains its antitumor efficacy, 
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1. Introduction
The pronounced general toxic effect of a large number 
of used cytostatics, rapidly developing resistance, and the 
lack of sensitivity of a number of tumors to existing drugs 
dictate the need to create new anticancer drugs.
The use of medicinal preparations based on licorice 
root has been around for several millennia. The main 
active ingredient in licorice root is the triterpenoid glycyr-
rhizic acid (GA). GA as a solubilizer of many water-in-
soluble organic substances is used to create low-dose, 
low-toxic drugs [1].
For example, practically insoluble in water, gossypol 
and its derivatives, hydrocortisone, prednisolone, kra-
cil, nistatine and other drugs in combination with the 
monoammonium salt of glycyrrhizic acid (MASGA) pass 
into aqueous solutions [2,3]. All these positive properties 
of GA and its derivatives are associated with its ability to 
form supramolecular complexes, which in aqueous solu-
tions have very low critical micelle concentration values. 
All researchers note the very low toxicity of preparations 
with GA, MASGK and their derivatives, created on their 
basis. In addition to the above properties, GA and its 
derivatives exhibit a pronounced anti-inflammatory, anal-
gesic effect, anti-edema, hypotensive, virus-neutralizing 
effect, improves tissue regeneration both in the early man-
ifestations of a viral disease and in ulcerative forms.
However, GA was not used for combination with an-
ticancer drugs. We are developing new promising sub-
stances based on tropolone alkaloidиs, of which dekocin, 
a derivative of the alkaloid colchicine, revealed activity 
in animal studies with 10 tumor strains, which was the 
highest (above 80%) on Sarcoma S 180, RShM-5 (cervi-
cal cancer) and AKATOL [4], which allowed this drug to 
be proposed for clinical trials. The obtained clinical data 
of the antitumor drug dekocin indicate a high sensitivity 
of skin cancer to 3-4% dekocin ointment, which was also 
effective in combination with radiation [5,6]. However, 
dekocin is insoluble in water, which complicates both its 
parenteral administration and bioavailability. In this re-
gard, we used the method of molecular encapsulation of 
the drug dekocin with glycyrrhizic acid (HA), which has 
effective solubilizing properties. A new water-soluble su-
pramolecular complex of Dekocin and HA was obtained, 
which differs in physicochemical parameters from the 
original Dekocin, as well as a 2.6-fold decrease in toxici-
ty, which is named Dekoglitz.
The aim of this work was to study the antitumor activ-
ity of a new colchicine derivative Dekoglitz in animals 
with tumor strains of Sarcoma 45 and ovarian tumor (OT) 
in comparison with the effect of decocin, 5-fluorouracil 
and etoposide, as well as to study the effect of Decoglitz 
on DNA/RNA synthesis and internucleosomal tumor deg-




Transplantable tumors, murine sarcoma 180, and two 
strains of rat sarcoma 45 and ovarian tumors (OT) were 
used in the work. Strain Sarcoma 180 was purchased from 
the Tumor Strains Collection Bank (Institute of Carcino-
genesis, N.N. Blokhin Russian Cancer Research Center, 
Russian Academy of Medical Sciences) Moscow, Russia. 
The strains of Sarcoma 45 and ovarian tumors (OT) were 
purchased from the Tumor Strains Collection Bank (Insti-
tute of Oncology of Kazakhstan). The tumor strains were 
passaged to the strain protocol.
2.2 Antitumor Drugs
The following drugs were used in the work: etoposide 
(Etoposide phosphate, Bristol-Myers Squibb); 5-fluoro-
uracil (Getwell Pharm acutikals, India); the K-18 (Deko-
cin) and its derivative Dekoglitz (tropolone alkaloids, col-
chicine derivatives) developed by Prof., Z. M. Enikeeva 
at the Republican Specialized Scientific Practical Medical 
Center of Oncology and Radiology of the Ministry of 
Health of the Republic of Uzbekistan (RSNPMTSO&R 
MH RUz).
2.3 Animals
In the experiment white outbred, mice weighing 18-20 
g (60 individuals) and rats weighing 90-140 g (68 indi-
viduals) were used. The animals were kept on a standard 
diet under natural lighting conditions and had free access 
to water and food in the vivarium at the RSNPMTSO&R 
MH RUz.
At the end of the experiment, all rats and mice were 
euthanized under ether anesthesia, in accordance with the 
International Rules for the Protection of Vertebrates. All 
experiments were performed in accordance with the recom-
mendations and requirements of the “World Society for the 
Protection of Animals (WSPA)” and “European Convention 
for the Protection of Experimental” (Strasbourg, 1986).
2.3.1 Investigation Antitumor Activity of Drugs
Tumor subinoculation was carried out according to gen-
erally accepted methods: tumors of Sarcoma 45 and OT 
were inoculated subcutaneously with a suspension of tumor 
cells, 30-60 mg in 0.3-0.5 ml of nutrient medium per rat 
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[7]. Treatment of animals began 4 days after tumor implan-
tation, drugs were injected in all groups 10 times, and all 
experimental groups were injected with drugs in a volume 
of 0.3 ml per 100 g rat. The animals were slaughtered on 
the 19-21st day after tumor implantation, the animals were 
sacrificed using humane methods of working with laborato-
ry animals. Before the introduction and at the end of the ex-
periment, the body weight of the animals was determined. 
During the experiment, in order to study the dynam-
ics of tumor growth, the volumes of tumors through the 
skin of animals were measured in the treated and control 
groups of mice (in 3 projections) at the beginning of the 
experiment, every 5 days after the start of treatment, and 
before slaughter. At the end of the experiment, the effica-
cy in sacrificed mice was determined by the volume (V) 
of the extracted tumor tissue, as well as by the tumor mass 
in the compared groups. Tumor growth inhibition was cal-
culated using the formulas [7]. The tolerability of the treat-
ment was judged by the death of the mice; for an indirect 
assessment of the possible hematotoxicity in the sacrificed 
mice, the spleen weight was determined.
2.3.2 Alkylating Action
The effect of drugs on the synthesis of DNA and RNA 
was studied on Sarcoma 180 tumor cells in vitro. A cell 
suspension from tumor tissue was obtained according to 
the method [8]. Cells with a titer of 10,000 were cultured in 
medium (RPMI-1640 containing 5% fetal bovine serum 
(FBS), 2mM L-glutamine, 10U/ml penicillin and 100mcg 
/ ml streptomycin), with the absence and presence of ther-
apeutic (TD) investigational drugs , for 24 hours at 370C 
in an atmosphere of 5% CO2.
2.3.3 Isolation of DNA/RNA
DNA/RNA preparations from Sarcoma 180 cells were 
isolated by two methods, a) phenol-chloroform method [9] 
and according to the protocol of the kit-kit “DNA-sorb-B” 
(InterLabService), Russia. The DNA/RNA concentration 
was determined by adsorption at a wavelength of 260 nm 
on an SF-26 spectrophotometer (Russia). 
For the analysis of internucleosomal DNA degradation, 
total DNA/RNA preparations were treated with the RNase 
A enzyme according by method [9]. DNA/RNA electro-
phoresis was analyzed in 1.5% agarose gel for 4 h, 60V 
according to the method [9].
Statistical processing was performed using Statistica, 
version 6.0. The level of statistical significance was taken 
as p <0.05.
3. Results
3.1 Study of Antitumor Activity, in vivo
The study of the antitumor activity of the drugs on the 
Sarcoma 45 strain began 4 days after tumor subinocula-
tion the drugs were injected 10 times. The slaughter was 
carried out on day 21. In the control group, there was a 
mortality of 25%, in the experimental groups with the use 
of dekoglits and dekocin, there was no death of animals, 
in the group with 5-fluorouracil all animals died after 10-
fold administration, in the group with etoposide, 30% of 
the animals died.
In group 2, the drug Dekoglitz showed high antitumor 
activity in 98/96%, 80% of regressed tumors were ob-
served, while the drug caused a slight decrease in body 
weight (by 5%) and an increase in the spleen by 20% (Ta-
ble 1).
In group 3, the antitumor effect of the drug dekocin 
was less high - 70/72%, the drug caused a slight decrease 
in body weight (by 6%) and spleen (by 20%).
In group 4, the drug 5-fluorouracil at a dose of 15 mg/
kg caused the death of all animals on day 15 after inoc-
ulation and its antitumor effect could be assessed on day 
12 when measuring the volume of tumors in 2 animals, 
which was in relation to the control for this day is 76%, 
however, due to the death of animals, it was impossible to 
assess the effect of the drug on body weight and spleen.
Table 1. Antitumor activity of the drug Dekoglitz in comparison with Dekocin, 5-FU and Etoposide in rats with tumor 
Sarcoma 45





The mass of animals
(gr) Tumor volume, (cm
3)
before after before after 5th day 12th day after
Control 8 6 131.0±9.3 121.3±9.0 0.3±0.04 2.1±0.5 2.7±0.8
Decoglitz 20 mg/kg 6 6 102.0±5.8 97.0±6.0 0.2±0.1 0.2±0.1 0.04±0.01*
Dekocin 15 mg/kg 6 6 132.0±17 124.0±14.4 0.1±0.02 0.5±0.13 0.8±0.07*
5-FU
15 mg/kg
6 0 109.0±4.4 - 0.1±0.05 0.48±0.08 -
Etoposide 8 mg/kg 6 4 114.0±9.0 106.0±8.0 0.2±0.1 0.7±0.16 0.6±0.16
Note: in the treatment groups n = 6, in the control n = 8; * differences are statistically significant in comparison with control at P <0.05.
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In the 5th group, the antitumor effect of the drug etopo-
side was 78/76%, the drug caused a slight decrease in 
body weight (by 7%) and a more pronounced decrease in 
the spleen weight (by 40%).
Thus, the new drug Dekoglitz showed the highest ac-
tivity, both in comparison with dekocin, from which it 
was obtained, and known cytostatics, moreover, its effect 
was higher than the comparison drugs by 20-28%, and 
there was no such side effect as the effect on the spleen. It 
should be noted that Dekoglitz was studied at a dose that 
in relation to LD50 was significantly lower than that of de-
kocin, i.e. for GA and MASGK derivatives, it was noted [10] 
that their activity manifests itself in doses 2-4 times less 
than the maximum tolerated.
The study of the antitumor activity of the drugs on 
the Ovarian Tumor (OT) strain began 4 days after tumor 
transplantation the drugs were injected 10 times. There 
was no death of animals during the experiment. The 
slaughter was carried out on the 19th day.
In group 2, the drug dekocin was 54/44% active, while 
the drug caused a slight decrease in body spleen weight (by 
11%) and an increase in body weight by 21% (Table 2).
In group 3, the antitumor effect of the drug Dekoglitz 
at a dose of 20 mg / kg with intraperitoneal injection was 
less high - 89/76% than when exposed to Sarcoma 45, 
but caused tumor regression in 40% of animals. The drug 
caused a slight decrease in the spleen (by 11%), body 
weight was 13% more than the initial one.
In the 4th group, the drug Dekoglitz at a dose of 40 mg/
kg with oral administration had a higher antitumor effect 
96/86%, while it caused tumor regression in 60% of ani-
mals, the drug had side effects only in a slight decrease in 
the spleen (by 11%), body weight was 26% more than the 
initial one.
3.2 Study of the Mechanism of Action, in vitro
The high antitumor activity of the drug Dekoglitz, as 
well as its further study as a cytostatic, involves the study 
of such aspects of its mechanism of action as alkylating, 
the influence on DNA/RNA synthesis, internucleosomal 
DNA degradation, and topoisomerase II activity. The ef-
fect of K-18 and Decoglitz on DNA and RNA synthesis 
was investigated in sarcoma 180 cells in vitro in com-
parison with etoposide, which is a known inhibitor of to-
poisomerase I/II.
Figure 1 shows the results of DNA/RNA electrophore-
Table 1. Continued.
Groups of animals Weight tumors (gr) Weight Spleen (mg)
% inhibition of tumor growth
by volume by mass % regression
Control 2.5±1.1 0.5±0.03
Decoglitz
20 mg/kg 0.04±0.01 0.6±0.04 98 96 80
Dekocin
15 mg/kg 0.7±0.07* 0.4±0.03 70 72 0
5-FU
15 mg/kg - - 77 - 0
Etoposide
8 mg/kg 0.6±0.06* 0.3±0.02 78 76 0
Table 2. Antitumor activity of the drug Dekoglitz in comparison with Dekocin in rats with ovarian tumor












before treatment after treatment for 8th day for 10th day by volume bymass
%
regression
Control 160±10.6 162±10.2 1.7±0.5 2.8±0.5 2.5±0,6 0.9±0.07
Dekocin,








110±3.2 139±5.7 0.6±0.1 0.1±0.01* 0.1±0.03* 0.8±0.1 96 86 60
Note: in the treatment groups n = 6, in the control n = 6; * differences are statistically significant in comparison with control at P <0.05.
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sis of tumor cells cultured in the absence of preparations 
(lanes 1,2) and using etoposide, K-18 and Dekoglitz (re-
spectively, lanes 4-6).
Figure 1. Influence of preparations on native DNA, nucle-
osoma degradation of DNA and activity topoisomerase II 
tumor cells of the Sarcoma 180, in vitro
Lanes 1 and 2 native DNA/ RNA of Sarcoma 180 (not 
treated with RNase A). Lanes 3-4, aliquots of DNA treat-
ed with RNase. Lane 3 control, without the using of cyto-
statics, Lane 4 Etoposide, Lane 5 K-18 (Dekocin), Lane 
6 Dekoglitz. Electrophoresis carries out in to 1.5 % ТАЕ 
agarose gel, 4h, and 60V and visualized by UV transillu-
minator after staining with ethidium bromide.
In aliquots of DNA/RNA not treated with the enzyme 
RNase, the electrophoregram shows a high native of nu-
clear DNA and RNA molecules (Figure 1, lanes 1, 2). In 
aliquots of DNA/RNA treated with the enzyme RNase, 
the electrophoregram shows DNA degradation in the form 
of a plume (Figure 1, lanes 4-6).
The results of the electrophoresis showed: Etoposide, 
K-18, and Dekoglitz contributed to internucleosomal 
DNA degradation by: 75.7 ± 3.3, 86.7 ± 3.7, and 94.5 ± 
1.7, respectively. Also, according to the pattern of DNA 
fragmentation, electrophoregram, Etoposide, K-18, and 
Dekoglitz inhibited topoisomerase II activity by 57.6 ± 2.7, 
64.6 ± 2.3, and 79.6 ± 3.0, respectively (Figure 1, Table 3).
Regarding the effect of the three drugs on topoisomer-
ase II (TOPO-II) of Sarcoma 180 tumor cells, the activity 
of this enzyme was determined visually by the pattern of 
electrophoresis of fragmented DNA in a gel. Etoposide, 
K-18, and Dekoglitz inhibited TOPO II activity by 57.6 
± 2.7, 64.6 ± 2.3, and 79.6 ± 3.0, respectively (Figure 1, 
Table 3).
The results, the effect of the studied drugs on the syn-
thesis of DNA/RNA showed: a) Etoposide, K-18 and 
Dekoglitz inhibited DNA synthesis by 64.9 ± 2.7, 85.6 ± 
2.3, 95.7 ± 3.7, respectively; b) Etoposide, K-18, and De-
koglitz inhibited RNA synthesis by 30.0 ± 3.0, 60.5 ± 1.7, 
65.9 ± 2.7, respectively (Table 3).
Table 3. Influence of antineoplastic preparations on syn-
thesis DNA/RNA, TOPO II activity and DNA nucleosoma 















Control 0±0 0±0 0±0 0±0
Etoposide
8 mkg/ml 75.7±3.3 57.6±2.7 64.9±2.7 30.0±3.0
K-18
15 mkg/ml 86.7±3.7 64.6±2.3 85.6±2.3 60.5±1.7
Decoglitz 
20 mkg/ml 94.5±1.7 79.6±3.0 95.7±3.7 65.9±2.7
Thus, the results of this experiment showed a high al-
kylating activity of Decoglitz to targets DNA/RNA and 
its inhibitory effect on topoisomerase II, resulting in DNA 
fragmentation, and then cell apoptosis.
4. Conclusion
The study of the new drug Dekoglitz on animals with 
a tumor of Sarcoma 45 revealed a very high activity with 
80% tumor regression, which was 20-27% more than the 
original Dekocin, 5-fluorouracil and etoposide with a low-
er level of side effects. Dekoglitz also had a high effect on 
OT tumor when administered intraperitoneal, which was 
30-40% higher than the effect of Dekocin (40% of tumors 
regressed), however, Dekoglitz showed an even higher 
activity after oral administration, where 60% of tumors 
regressed.
This Dekoglitz effect is confirmed by a more intense 
effect on the synthesis of DNA and RNA of tumor cells. 
Apparently, the great ability to suppress the synthesis of 
NA and the activity of topoisomerase II and to carry out in-
ternucleosomal degradation of tumor DNA by the new drug 
Dekoglitz explains its antitumor efficacy, which is greater 
than that of Dekocin (K-18) in experiments on tumors.
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